TRIAL DETAIL
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 03/01/2008 |
Age of Trial (yrs) 17.1 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
HSP90 inhibitor |
|||
Strategy: |
Destroy KIT |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
B1311003, PO7318 |
|||
Sponsor: |
Pfizer,
NCI |
|||
Patient Contact: |
Pfizer Oncology Clinical Trial Information Service
1-877-369-9753
PfizerCancerTrials@emergingmed.com
Pfizer CT.gov Call Center
1-800-718-1021 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
SNX-5422 is an oral HSP90 inhibitor made by Seranex. This phase I trial allows patients with solid tumors or lymphomas. Phase I trials are designed to evaluate the safety of a drug and to establish safe/tolerable levels for later trials. The development of SNX-5422 has been discontinued because of ocular toxicity seen in animal models and in a phase I study. Clin Cancer Res; 17(21); 1–9. ©2011 AACR. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Bethesda |
MD |
20982 |
USA |